Second-generation Drug-eluting Stents in Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1164 participants.
Also called NCT03321032
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,164 participants
- Registry
-
NCT03321032
-
- Other papers using this trial's data
- Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial
- Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Unknown status
Technical summary
Registry record NCT03321032. Randomized; double masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2021-01-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Second-generation Drug-eluting Stents in Diabetes
- Acronym
- SUGAR
- Condition
- Coronary Artery Disease
- Condition
- Diabetes Mellitus
- Intervention (Device)
- Polymer-free amphilimus-eluting stents
- Intervention (Device)
- Biolinx Polymer-based zotarolimus-eluting stents
- Lead sponsor
- Spanish Society of Cardiology
Record details
- Record id
cardio:ct-nct03321032- Content hash
827e53a2fec5961ad430dd735cf2aab39f5aff13545336cf814ee438b3d27f62